Atossa Therapeutics, Inc. (ATOS)
2.25
-0.12
(-5.06%)
USD |
NASDAQ |
Oct 29, 16:00
2.25
0.00 (0.00%)
After-Hours: 20:00
Atossa Therapeutics Enterprise Value : -2.553M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | -2.553M |
| October 27, 2026 | -2.453M |
| October 26, 2026 | -1.755M |
| October 23, 2026 | -0.2578M |
| October 22, 2026 | 0.9397M |
| October 21, 2026 | -0.9564M |
| October 20, 2026 | -0.8566M |
| October 19, 2026 | -0.657M |
| October 16, 2026 | 2.836M |
| October 15, 2026 | 0.2411M |
| October 14, 2026 | 1.538M |
| October 13, 2026 | -0.657M |
| October 12, 2026 | -2.366M |
| October 09, 2026 | -1.854M |
| October 08, 2026 | -2.054M |
| October 07, 2026 | -1.655M |
| October 06, 2026 | -1.755M |
| October 05, 2026 | -1.755M |
| October 02, 2026 | -2.852M |
| October 01, 2026 | -3.551M |
| September 30, 2026 | -6.744M |
| September 29, 2026 | -6.345M |
| September 28, 2026 | -6.645M |
| September 25, 2026 | -7.243M |
| September 24, 2026 | -5.746M |
| Date | Value |
|---|---|
| September 23, 2026 | -4.449M |
| September 22, 2026 | -3.651M |
| September 21, 2026 | -3.751M |
| September 18, 2026 | -4.05M |
| September 17, 2026 | -2.254M |
| September 16, 2026 | -2.054M |
| September 15, 2026 | -2.553M |
| September 14, 2026 | -1.455M |
| September 11, 2026 | -1.156M |
| September 10, 2026 | -2.852M |
| September 09, 2026 | -2.254M |
| September 08, 2026 | -1.106M |
| September 04, 2026 | -1.056M |
| September 03, 2026 | -0.9564M |
| September 02, 2026 | -1.655M |
| September 01, 2026 | -2.054M |
| August 31, 2026 | -1.256M |
| August 28, 2026 | -0.4574M |
| August 27, 2026 | 0.1414M |
| August 26, 2026 | 0.2411M |
| August 25, 2026 | 0.5405M |
| August 24, 2026 | 0.1414M |
| August 21, 2026 | -0.8566M |
| August 20, 2026 | -0.3576M |
| August 19, 2026 | 0.1414M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.615B |
| Alnylam Pharmaceuticals, Inc. | 30.76B |
| Anika Therapeutics, Inc. | 275.24M |
| Savara, Inc. | 888.48M |
| Vericel Corp. | 2.035B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.491M |
| Total Expenses (Quarterly) | 8.491M |
| EPS Diluted (Quarterly) | -0.9531 |
| Earnings Yield | -193.1% |
| Normalized Earnings Yield | -193.10 |